Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 6/29/15  and contains information from public web pages and contributions from the ZoomInfo community.

Mr. David L. Hallal

Wrong David L. Hallal?

Chief Executive Officer

Alexion Pharmaceuticals Inc
352 Knotter Drive
Cheshire , Connecticut 06511
United States

Company Description: Alexion Pharmaceuticals, Inc. (Alexion) is a biopharmaceutical company engaged in the discovery, development and delivery of biologic therapeutic products for the...   more
Background

Employment History

Education

  • BA
    University of New Hampshire
  • bachelor of arts degree
    University of New Hampshire
  • B.A. , psychology
    University of New Hampshire
  • bachelor of arts
    University of New Hampshire
64 Total References
Web References
David Hallal, Chief ...
alexionpharm.com, 30 Jan 2015 [cached]
David Hallal, Chief Operating Officer
David Hallal is Chief Operating Officer of Alexion Pharmaceuticals. In this position, he leads key enterprise-wide initiatives that focus on diverse aspects of our operations. Mr. Hallal also leads our commercial organization globally, and also has responsibility for all country operations in each of Alexion's affiliates in Europe/Middle East/Africa (EMEA), Japan, Australasia and Latin America. Mr. Hallal joined Alexion in 2006. Under his leadership, he formulated and implemented from inception Alexion's global commercial organization to support Soliris ® (eculizumab) as our industry's most successful ultra-orphan drug launch, currently approved to treat patients with PNH and aHUS.
Mr. Hallal has more than 25 years of experience in the biopharmaceutical industry. Before joining Alexon in 2006, Mr. Hallal served as Vice President, Sales at OSI Eyetech, and held various commercial leadership positions at Amgen and Biogen Idec where he was involved in multiple blockbuster product launches in the areas of hematology, oncology, nephrology and immunology.
Mr. Hallal holds a BA from the University of New Hampshire.
...
David Hallal, Chief Operating Officer
David Hallal has been Chief Operating Officer of Alexion Pharmaceuticals since September 2014. In this position, he leads key enterprise-wide initiatives that focus on diverse aspects of our operations. Mr. Hallal also leads our commercial organization globally, and also has responsibility for all country operations in each of Alexion's affiliates in Europe/Middle East/Africa (EMEA), Japan, Australasia and Latin America. Mr. Hallal joined Alexion in 2006. Under his leadership, he formulated and implemented from inception Alexion's global commercial organization to support Soliris ® (eculizumab) as our industry's most successful ultra-orphan drug launch, currently approved to treat patients with PNH and aHUS.
Mr. Hallal has more than 25 years of experience in the biopharmaceutical industry. Before joining Alexon in 2006, Mr. Hallal served as Vice President, Sales at OSI Eyetech, and held various commercial leadership positions at Amgen and Biogen Idec where he was involved in multiple blockbuster product launches in the areas of hematology, oncology, nephrology and immunology.
Mr. Hallal holds a BA from the University of New Hampshire.
David Hallal, Executive Vice ...
www.alexionpharm.com, 23 April 2014 [cached]
David Hallal, Executive Vice President, Chief Commercial Officer
David Hallal is Executive Vice President, Chief Commercial Officer of Alexion Pharmaceuticals. In this position, he is responsible for all commercial functions in the United States, EMEA, Japan, Latin America, and Australasia. Mr. Hallal also oversees Alexion's Global Therapeutic Franchises across all territories, which now include Hematology, Nephrology, and Metabolic Disorders. He joined Alexion in 2006 to build the company's first commercial organization, and led the highly successful U.S. launch of the company's first product, Soliris ® (eculizumab) for PNH and in 2008, as Alexion expanded its commercial operations, Mr. Hallal helped to lead the global launch of PNH. Today, he is leading an expanded global team for the launch of Soliris in its second indication, atypical hemolytic uremic syndrome (aHUS), and preparing the organization to serve patients globally with neurological, metabolic and other life-threatening and ultra-rare disorders.
Mr. Hallal has more than 25 years of experience in the biopharmaceutical industry. Before joining Alexon in 2006, Mr. Hallal served as Vice President, Sales at OSI Eyetech where he led the launch of a first-in-class anti-VEGF therapy for age-related macular degeneration. He also spent 13 years with Amgen and Biogen Idec where he held various commercial leadership positions and was involved in multiple blockbuster product launches in the areas of hematology, oncology, nephrology and immunology. Mr. Hallal holds a BA from the University of New Hampshire.
David Hallal is being ...
www.rxir.com, 17 Sept 2014 [cached]
David Hallal is being promoted to the newly created position of Chief Operating Officer and has been appointed to Alexion's Board of Directors. Mr. Hallal had previously served as Executive Vice President and Chief Commercial Officer, and will continue to lead all commercial operations globally with responsibility for country operations in each of Alexion's affiliates in EMEA, Japan, Australasia, and Latin America. As Chief Operating Officer, Mr. Hallal will additionally now lead key enterprise-wide initiatives at the senior level, and he will expand his role with external stakeholders.
"David's focus and commitment to patient care and strong leadership across our operations are an important component of the foundation for Alexion's future growth," said Leonard Bell, M.D., Chief Executive Officer of Alexion.
...
The promotions of Mr. Hallal, Ms. Carmichael, and Mr. Moriarty, and the addition of Mr. Miller, are designed to facilitate the further growth of Alexion to serve more patients with severe and devastating disorders around the world.
...
David L. Hallal Mr. Hallal joined Alexion in 2006 to initiate the Company's US commercial operations, and has played the principal role in building Alexion's successful global commercial platform to serve patients with severe and life-threatening rare disorders. From his initial role where he led the highly successful U.S. launch of the Company's first product, Soliris® (eculizumab) in 2007, Mr. Hallal has progressively expanded his responsibilities to Chief Commercial Officer. In addition to his leadership of all commercial operations globally, Mr. Hallal has responsibility for country operations in each of Alexion's affiliates in EMEA, Japan, Australasia, Latin America. Mr. Hallal serves on all key management decision-making committees. Mr. Hallal has more than 25 years of experience in the biopharmaceutical industry, and prior to Alexion he held commercial leadership positions at OSI Eyetech, Biogen Idec and Amgen. Mr. Hallal holds a BA from the University of New Hampshire.
Alexion Pharmaceuticals - Management Team
www.alxn.com, 5 July 2013 [cached]
David Hallal Executive Vice President, Chief Commercial Officer
...
David Hallal - Executive Vice President, Chief Commercial Officer
David Hallal is Executive Vice President, Chief Commercial Officer of Alexion Pharmaceuticals. In this position, he is responsible for all commercial functions in the United States, EMEA, Japan, Latin America, and Australasia. Mr. Hallal also oversees Alexion's Global Therapeutic Franchises across all territories, which now include Hematology, Nephrology, and Metabolic Disorders. He joined Alexion in 2006 to build the company's first commercial organization, and led the highly successful U.S. launch of the company's first product, Soliris® (eculizumab) for PNH and in 2008, as Alexion expanded its commercial operations, Mr. Hallal helped to lead the global launch of PNH. Today, he is leading an expanded global team for the launch of Soliris in its second indication, atypical hemolytic uremic syndrome (aHUS), and preparing the organization to serve patients globally with neurological, metabolic and other life-threatening and ultra-rare disorders.
Mr. Hallal has more than 25 years of experience in the biopharmaceutical industry. Before joining Alexon in 2006, Mr. Hallal served as Vice President, Sales at OSI Eyetech where he led the launch of a first-in-class anti-VEGF therapy for age-related macular degeneration. He also spent 13 years with Amgen and Biogen Idec where he held various commercial leadership positions and was involved in multiple blockbuster product launches in the areas of hematology, oncology, nephrology and immunology.
Mr. Hallal holds a BA from the University of New Hampshire.
Alexion Pharmaceuticals - Alexion Pharma - - Commercial Leadership Executive With Experience in First-in-Class Biotech Product Launches and Blockbuster Hematology/Oncology Products -
www.alxn.com [cached]
Alexion Pharmaceuticals Appoints David L. Hallal Vice President U.S. Commercial Operations Alexion Pharmaceuticals - Alexion Pharma - - Commercial Leadership Executive With Experience in First-in-Class Biotech Product Launches and Blockbuster Hematology/Oncology Products -
Alexion Pharmaceuticals
...
Alexion Pharmaceuticals Appoints David L. Hallal Vice President U.S. Commercial Operations
- Commercial Leadership Executive With Experience in First-in-Class Biotech Product Launches and Blockbuster Hematology/Oncology Products -
Alexion Pharmaceuticals Appoints David L. Hallal Vice President U.S. Commercial Operations
Alexion Pharmaceuticals Appoints David L. Hallal Vice President U.S. Commercial Operations
- Commercial Leadership Executive With Experience in First-in-Class Biotech Product Launches and Blockbuster Hematology/Oncology Products -
CHESHIRE, Conn., July 6 -- Alexion Pharmaceuticals, Inc. announced today that it has appointed David L. Hallal as Vice President U.S. Commercial Operations. Reporting to David Keiser, President and Chief Operating Officer, Mr. Hallal will direct the expected launch of Soliris(TM) in the U.S., with responsibility for all U.S. commercial operations including sales, marketing, reimbursement and corporate account management, and customer relations.
...
"I am excited to have David join the Alexion senior management team and to lead the anticipated U.S. sales launch for Soliris in PNH," said Leonard Bell, M.D., Chief Executive Officer of Alexion.
...
"David has proven sales leadership and pharmaceutical product launch experience with five different biotech products, including first-in-class drugs, as well as hematology/oncology blockbuster products. David is a proven and tested sales and marketing leader with whom I look forward to collaborating as we move Soliris toward the U.S. marketplace."
Mr. Hallal, 40, has more than 17 years of commercial experience in the pharmaceutical industry. He joins Alexion from OSI Eyetech where, since 2004, he was Vice President of Sales. There he led the U.S. launch of the first-in-class anti-VEGF therapy, Macugen for age-related macular degeneration. Based on sales, Macugen became the most successful product launch in ophthalmology. Prior, Mr. Hallal was Senior Director of Sales for Biogen Idec's Immunology Sales Team, where he built a sales organization dedicated to the launch of the first-in-class biologic Amevive for psoriasis.
For more than ten years starting in 1992, Mr. Hallal held various leadership positions at Amgen, focusing on the blockbuster brands Epogen, Neupogen, Neulasta and Aranesp in the hematology and oncology marketplace. More specifically from 1999 to 2002, he served as the Southeast Oncology Sales Director and then helped Amgen build its first dedicated hospital sales team. During this time, Mr. Hallal played an integral role in pre-launch planning and the launch of Aranesp and Neulasta. From 1998 to 1999, Mr. Hallal served as Amgen's Director of Oncology National Accounts, where he played a significant role in developing key long-term partnerships with the nation's largest oncology practice management groups and physician group purchasing organizations. From 1992 to 1998, Mr. Hallal served in roles of escalating responsibility for the promotion of Epogen and Neupogen, including National Account Manager where he was responsible for forging relationships with many of the largest managed care organizations in the U.S. He holds a B.A. in psychology from the University of New Hampshire.
"David has demonstrated extensive operational and strategic capabilities in all areas of commercial launches for a variety of novel biopharmaceuticals in the U.S.," said David Keiser, President and Chief Operating Officer of Alexion.
Other People with the name "Hallal":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304